Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03053193 · ClinicalTrials.gov registry record
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
A clinical trial of Breast Cancer, sponsored by Agendia.
- Recruiting
- Registry status
- 30,000
- Enrollment target
- 20
- Study locations
NCT03053193: Recruiting study of Breast Cancer, sponsored by Agendia.
NCT03053193 is a study of Breast Cancer that is actively recruiting participants, run by Agendia. The registered enrollment target is 30,000 participants, above the 2,779-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (980% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03053193, a study of Breast Cancer, is actively recruiting participants, sponsored by Agendia.
- RECRUITING
- Registry status
- 30,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Primary Outcome
Create a large scale registry of full genome expression data with clinical data to investigate possible new gene associations with prognostic or predictive value.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MammaPrint, BluePrint, and Full-Genome Testing
Study Locations (20)
California
- Adventist Health - Bakersfield - Bakersfield
- Comprehensive Cancer Center at Desert Regional Medical Center - Palm Springs
- North Valley Breast Clinic - Redding
- UCSF Breast Care Center - San Francisco
- Valley Breast Care - Van Nuys
Colorado
- Rocky Mountain Cancer Centers - Aurora
- University of Colorado Cancer Center - Aurora
- Comprehensive Breast Care of Denver - Denver
- Rocky Mountain Cancer Center - Lakewood - Lakewood
- Vail Health - Shaw Cancer Center - Vail
Florida
- Breast Specialists of South Florida - Atlantis
- JFK Medical Center - Atlantis
- Boca Raton Regional Hospital - Boca Raton
- Morton Plant Hospital - Clearwater
Arizona
- Arizona Oncology Associates, PC - Phoenix
- Arizona Oncology Associates, PC - HOPE - Tucson
Alabama
- CHS Grandview - Birmingham
Alaska
- Providence Alaska Medical Center - Anchorage
Connecticut
- St. Mary's Hospital - Waterbury
Delaware
- Medical Oncology and Hematology Consultants - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,000 participants |
| Start Date | 2017-04-28 |
| Est. Completion | 2037-12 |
What NCT03053193 shows while recruiting
NCT03053193 is an observational study that tracks outcomes without assigning an intervention. Its 30,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,779-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (980% higher).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which MammaPrint, BluePrint, and Full-Genome Testing is the first listed.
NCT03053193 names 20 study sites across 8 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT03053193 about?
NCT03053193 is a clinical study titled "MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles". The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable...
What is the current status of trial NCT03053193?
This trial is currently recruiting. The enrollment target is 30,000 participants. The study started on 2017-04-28. Estimated completion is 2037-12.
What conditions does trial NCT03053193 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03053193?
The interventions under investigation include: MammaPrint, BluePrint, and Full-Genome Testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03053193?
This trial is sponsored by Agendia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03053193 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03053193's enrollment target sits among peer trials
30,000 6th of 1224 higher than 1,219 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03689595 · 30,000 participants
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
- NCT04834869 · 30,000 participants
COVID-19 Vaccines Safety Tracking (CoVaST)
- NCT05484804 · 30,000 participants · NA
Accountability for Care Through Undoing Racism & Equity for Moms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI